raltegravir
4 articles related to "raltegravir"
-
Final hearings begin in Bayer's appeal against Indian move to allow production of more affordable cancer drug
Further compulsory licences on high-price patented medicines expected 18 January 2013 - This week, final hearings began in Chennai, India, in the appeal that German pharmaceutical company Bayer...
Statements, Speeches, Letters – Last updated 18 January 2013
msfaccess.org/content/final-hearings-begin-bayers-appeal-against-indian-move-allow-production-more-affordable -
Bayer attempts block on affordable patented drugs in India
German company appeals against life-saving compulsory licence decision in India Geneva/New Delhi, 3 September, 2012 – German pharmaceutical company Bayer today heads to India’s Intellectual...
Press Release – Last updated 26 September 2012
msfaccess.org/about-us/media-room/press-releases/bayer-attempts-block-affordable-patented-drugs-india -
Caught in the Middle – HIV Medicines Pricing Sky High in ‘Middle-Income’ Countries
Each year, MSF publishes a survey of the latest prices for antiretroviral medicines to treat people living with HIV/AIDS in developing countries. It started out as a way of offering a practical guide...
Web article – Last updated 08 August 2011
msfaccess.org/content/caught-middle-%E2%80%93-hiv-medicines-pricing-sky-high-%E2%80%98middle-income%E2%80%99-countries -
DDT July 08: How developing country concerns need to be part of drug development
Clinical trials are usually designed to meet registration requirements in developed countries, and do not always address key concerns for use in developing countries. Four late-stage investigational...
In Medical Journals / Research Articles – Last updated 29 July 2008
msfaccess.org/content/ddt-july-08-how-developing-country-concerns-need-be-part-drug-development
↑ To top
